SA522433360B1 - L-أَسْباراجيناز مُعدل - Google Patents
L-أَسْباراجيناز مُعدلInfo
- Publication number
- SA522433360B1 SA522433360B1 SA522433360A SA522433360A SA522433360B1 SA 522433360 B1 SA522433360 B1 SA 522433360B1 SA 522433360 A SA522433360 A SA 522433360A SA 522433360 A SA522433360 A SA 522433360A SA 522433360 B1 SA522433360 B1 SA 522433360B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- modified protein
- asparaginase
- poly
- modified
- amino acid
- Prior art date
Links
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 title abstract 4
- 108010024976 Asparaginase Proteins 0.000 title abstract 4
- 102000035118 modified proteins Human genes 0.000 abstract 5
- 108091005573 modified proteins Proteins 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 241000588698 Erwinia Species 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523061P | 2017-06-21 | 2017-06-21 | |
| EP17177237.9A EP3418383A1 (en) | 2017-06-21 | 2017-06-21 | Modified l-asparaginase |
| US15/671,086 US10174302B1 (en) | 2017-06-21 | 2017-08-07 | Modified L-asparaginase |
| PCT/EP2018/066647 WO2018234492A1 (en) | 2017-06-21 | 2018-06-21 | L-ASPARAGINASE MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA522433360B1 true SA522433360B1 (ar) | 2024-06-23 |
Family
ID=64737515
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522433360A SA522433360B1 (ar) | 2017-06-21 | 2019-12-21 | L-أَسْباراجيناز مُعدل |
| SA519410870A SA519410870B1 (ar) | 2017-06-21 | 2019-12-21 | أَسْباراجيناز مُعدل l- |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519410870A SA519410870B1 (ar) | 2017-06-21 | 2019-12-21 | أَسْباراجيناز مُعدل l- |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3642340B1 (enExample) |
| JP (2) | JP7808424B2 (enExample) |
| KR (1) | KR102727396B1 (enExample) |
| CN (1) | CN111315878B (enExample) |
| AU (1) | AU2018287145B2 (enExample) |
| BR (1) | BR112019027479A2 (enExample) |
| CA (1) | CA3068100A1 (enExample) |
| DK (1) | DK3642340T3 (enExample) |
| ES (1) | ES2979314T3 (enExample) |
| FI (1) | FI3642340T3 (enExample) |
| IL (1) | IL271504B2 (enExample) |
| MX (2) | MX2019015502A (enExample) |
| SA (2) | SA522433360B1 (enExample) |
| SG (1) | SG11201912625QA (enExample) |
| WO (1) | WO2018234492A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7065772B2 (ja) | 2015-12-22 | 2022-05-12 | エクスエル‐プロテイン ゲーエムベーハー | 低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸 |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| ES2979314T3 (es) * | 2017-06-21 | 2024-09-25 | Jazz Pharmaceuticals Ireland Ltd | L-asparaginasa modificada |
| EP3713595A1 (en) * | 2017-11-22 | 2020-09-30 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| CA3156066A1 (en) * | 2019-10-25 | 2021-04-29 | Mi Rim Choi | Recombinant l-asparaginase |
| KR20230125179A (ko) * | 2020-12-23 | 2023-08-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 전하-차폐 융합 단백질의 정제 방법 |
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US20260007728A1 (en) | 2022-07-14 | 2026-01-08 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8519753D0 (en) * | 1985-08-06 | 1985-09-11 | Health Lab Service Board | Production of 1-asparaginase |
| GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| EP2851424B1 (en) * | 2007-03-09 | 2016-09-21 | Novozymes A/S | Thermostable asparaginases |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| DK2571510T3 (en) * | 2010-05-21 | 2018-11-19 | Xl Protein Gmbh | BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| ES2979314T3 (es) | 2017-06-21 | 2024-09-25 | Jazz Pharmaceuticals Ireland Ltd | L-asparaginasa modificada |
-
2018
- 2018-06-21 ES ES18731853T patent/ES2979314T3/es active Active
- 2018-06-21 EP EP18731853.0A patent/EP3642340B1/en active Active
- 2018-06-21 CA CA3068100A patent/CA3068100A1/en active Pending
- 2018-06-21 MX MX2019015502A patent/MX2019015502A/es unknown
- 2018-06-21 SG SG11201912625QA patent/SG11201912625QA/en unknown
- 2018-06-21 DK DK18731853.0T patent/DK3642340T3/da active
- 2018-06-21 CN CN201880054251.4A patent/CN111315878B/zh active Active
- 2018-06-21 FI FIEP18731853.0T patent/FI3642340T3/fi active
- 2018-06-21 KR KR1020207002029A patent/KR102727396B1/ko active Active
- 2018-06-21 EP EP22204187.3A patent/EP4180525A1/en active Pending
- 2018-06-21 JP JP2019571042A patent/JP7808424B2/ja active Active
- 2018-06-21 AU AU2018287145A patent/AU2018287145B2/en active Active
- 2018-06-21 BR BR112019027479-0A patent/BR112019027479A2/pt unknown
- 2018-06-21 WO PCT/EP2018/066647 patent/WO2018234492A1/en not_active Ceased
- 2018-06-21 IL IL271504A patent/IL271504B2/en unknown
-
2019
- 2019-12-18 MX MX2024015050A patent/MX2024015050A/es unknown
- 2019-12-21 SA SA522433360A patent/SA522433360B1/ar unknown
- 2019-12-21 SA SA519410870A patent/SA519410870B1/ar unknown
-
2023
- 2023-02-28 JP JP2023030460A patent/JP7770352B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111315878A (zh) | 2020-06-19 |
| JP2020528743A (ja) | 2020-10-01 |
| AU2018287145B2 (en) | 2024-04-18 |
| JP2023081915A (ja) | 2023-06-13 |
| EP3642340B1 (en) | 2024-03-20 |
| WO2018234492A1 (en) | 2018-12-27 |
| RU2020101972A3 (enExample) | 2021-11-09 |
| AU2018287145A1 (en) | 2020-02-06 |
| RU2020101972A (ru) | 2021-07-21 |
| CN111315878B (zh) | 2024-04-26 |
| IL271504B1 (en) | 2024-01-01 |
| MX2019015502A (es) | 2020-07-28 |
| SG11201912625QA (en) | 2020-01-30 |
| IL271504B2 (en) | 2024-05-01 |
| KR20200030065A (ko) | 2020-03-19 |
| EP4180525A1 (en) | 2023-05-17 |
| FI3642340T3 (fi) | 2024-06-18 |
| BR112019027479A2 (pt) | 2020-09-15 |
| KR102727396B1 (ko) | 2024-11-08 |
| SA519410870B1 (ar) | 2023-03-06 |
| MX2024015050A (es) | 2025-01-09 |
| JP7808424B2 (ja) | 2026-01-29 |
| IL271504A (en) | 2020-02-27 |
| JP7770352B2 (ja) | 2025-11-14 |
| ES2979314T3 (es) | 2024-09-25 |
| DK3642340T3 (da) | 2024-06-03 |
| EP3642340A1 (en) | 2020-04-29 |
| CA3068100A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015502A (es) | L-asparaginasa modificada. | |
| EA201101553A1 (ru) | Полипептид, деградирующий углеводы, и его применения | |
| MX2023001394A (es) | Genes del factor viii optimizados. | |
| EP4467650A3 (en) | Scaffold proteins | |
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| MX2020012332A (es) | Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo. | |
| MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| MX2012015139A (es) | Polipéptido que tiene o que ayuda en la actividad de degradación del material de carbohidratos y usos del mismo. | |
| MX2012015142A (es) | Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo. | |
| IN2012DN02981A (enExample) | ||
| WO2011036443A9 (en) | S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders | |
| EP4306123A3 (en) | Saposin-a derived peptides and uses thereof | |
| IN2014DN09963A (enExample) | ||
| AR071534A1 (es) | Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa | |
| MY195726A (en) | Steviol Glycoside Transport | |
| MY167485A (en) | Recombinant human interferon-like proteins | |
| PH12018500468A1 (en) | Fusion protein | |
| DE60138558D1 (de) | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung | |
| ZA202304029B (en) | Cxcl9 and variants thereof for immunotherapy of cancer diseases | |
| EA201300059A1 (ru) | Полипептид, обладающий активностью сволленина, и его применение | |
| PH12017502323B1 (en) | Novel xylanase | |
| WO2019152418A3 (en) | Anti-inflammatory compounds and methods of use | |
| RU2018107330A (ru) | Индуктор иммунитета | |
| MX2020007336A (es) | Metodos y composiciones para modular la disfuncion de celulas endoteliales. |